210 related articles for article (PubMed ID: 26466969)
1. Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.
Aira LE; Hernández P; Prada D; Chico A; Gómez JA; González Z; Fuentes K; Viada C; Mazorra Z
MAbs; 2016; 8(1):187-95. PubMed ID: 26466969
[TBL] [Abstract][Full Text] [Related]
2. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z
MAbs; 2014; 6(3):783-93. PubMed ID: 24594862
[TBL] [Abstract][Full Text] [Related]
3. Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study.
Chopra A; Chandrashekara S; Iyer R; Rajasekhar L; Shetty N; Veeravalli SM; Ghosh A; Merchant M; Oak J; Londhey V; Barve A; Ramakrishnan MS; Montero E
Clin Rheumatol; 2016 Apr; 35(4):1059-64. PubMed ID: 26050104
[TBL] [Abstract][Full Text] [Related]
4. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
Rodríguez PC; Prada DM; Moreno E; Aira LE; Molinero C; López AM; Gómez JA; Hernández IM; Martínez JP; Reyes Y; Milera JM; Hernández MV; Torres R; Avila Y; Barrese Y; Viada C; Montero E; Hernández P
Clin Exp Immunol; 2018 Feb; 191(2):229-239. PubMed ID: 28963724
[TBL] [Abstract][Full Text] [Related]
5. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
[TBL] [Abstract][Full Text] [Related]
6. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
9. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha.
Williams RO
Methods Mol Biol; 2007; 361():265-84. PubMed ID: 17172717
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
11. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Rodriguez PC; Torres-Moya R; Reyes G; Molinero C; Prada D; Lopez AM; Hernandez IM; Hernandez MV; Martinez JP; Hernandez X; Casaco A; Ramos M; Avila Y; Barrese Y; Montero E; Hernandez P
Results Immunol; 2012; 2():204-11. PubMed ID: 24371585
[TBL] [Abstract][Full Text] [Related]
12. Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis.
Pai G; Pai AH
Case Rep Dermatol; 2017; 9(2):141-145. PubMed ID: 29033818
[TBL] [Abstract][Full Text] [Related]
13. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
Dogra S; Uprety S; Suresh SH
Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis.
Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ
Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317
[TBL] [Abstract][Full Text] [Related]
15. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
16. [Pathological mechanisms in rheumatoid arthritis].
Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1147-52. PubMed ID: 23961659
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients.
Cutolo M; Capellino S; Montagna P; Sulli A; Seriolo B; Villaggio B
Ann Rheum Dis; 2006 Jun; 65(6):728-35. PubMed ID: 16269423
[TBL] [Abstract][Full Text] [Related]
18. [Pathogenic cells of rheumatic inflammation as the target of modern therapies].
Kalden JR
Z Rheumatol; 2015 Feb; 74(1):8-13. PubMed ID: 25676124
[TBL] [Abstract][Full Text] [Related]
19. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
